Key Highlights

  • The Waters combination closed; BD shareholders received about 0.135 Waters shares per BD share plus a 39.2% stake in the combined company, and BD banked a $4 billion cash distribution.
  • Continuing operations grew 2.6% currency-neutral in the March 2026 quarter, with Interventional (+5.3%) offsetting a 1.8% decline in BioPharma Systems; full-year adjusted EPS guidance was raised to $12.52–$12.72.
  • At $165.62, BDX trades on a 12.57 forward P/E with a 6.69% free Cash Flow Yield , a discount to Medtronic that reflects slow organic growth and unresolved Alaris timing.
  • The transaction that defined BD's last two years is complete.

The separation is finished, not pending

Dickinson (NYSE:BDX). The transaction that defined BD's last two years is complete. The company spun off its Biosciences and Diagnostic Solutions businesses and merged them with a Waters Subsidiary in a tax-efficient Reverse Morris Trust valued at roughly $17.5 billion when announced. BD shareholders of record on 5 February received about 0.135 Waters shares for each BD share, leaving them with approximately 39.2% of the enlarged Waters against 60.8% for legacy Waters holders. BD also collected a $4 billion cash distribution ahead of closing, earmarked at announcement for a mix of Buybacks and Debt reduction.

That was the endgame of a campaign that began publicly in February 2025, when Starboard Value met management and wrote to the board urging a sale of the life sciences unit. Starboard never disclosed its stake size, but the board moved within five months. Attention now shifts to fiscal third-quarter results, due before the open, only the second full quarter of the post-separation company.

The share price has not obviously rewarded it

BDX closed at $165.62 at last closing, near the middle of a 52-week range of $140.11 to $213.08 and about 8.8% lower over the past year, giving a market Capitalization of $45.6 billion. Read alone, that looks like a strategy the market rejected.

The comparison is misleading, because the spin mechanically removed value from the BD share price. A holder of one BD share through the Record Date also received roughly 0.135 Waters shares, worth about $50.94 at Waters' close of $377.31 on 31 July. Adding that back puts the combined position near $216 per original BD share, above the pre-separation high. The transformation has created value; most of it has accrued inside Waters, whose market capitalization more than doubled on the share issuance and which trades on a forward multiple roughly double BD's.

What is left, and how it is growing

Continuing BD reports through four segments adopted. In the March 2026 quarter, Interventional was the standout at $1.357 billion, up 5.3% on a currency-neutral basis, spanning peripheral intervention, surgery and urology. Medical Essentials, the largest at $1.647 billion, grew only 1.7%; Connected Care, home to medication management and dispensing, rose 3.2% to $1.120 billion. BioPharma Systems, prefillable syringes and drug-delivery systems sold to pharmaceutical customers, fell 1.8% to $590 million, a reminder that BD's exposure to injectable Biologics is lumpy rather than linear.

Total Revenue was $4.714 billion, up 5.2% as reported and 2.6% currency-neutral. Most of the portfolio is consumable and recurring, tied to procedure volumes and hospital operating budgets rather than capital cycles, which is why BD's revenue line rarely swings hard in either direction.

The financial picture is better than the headline EPS

Adjusted diluted Earnings from continuing operations were $2.90 per share, up 3.9%, while the GAAP result was a $0.13 per-share loss on separation-related charges and a $274 million after-tax loss from discontinued operations. Half-year adjusted EPS of $5.38 was down 3.4% year over year, the cost of losing a high-margin diagnostics Business before the remaining company's Leverage and share count adjust.

BD raised full-year fiscal 2026 adjusted EPS guidance to $12.52–$12.72 from $12.35–$12.65, with revenue growth guided to low single digits currency-neutral. Chief executive Tom Polen described a quarter in which "revenue, margins and EPS" all came in ahead of plan, citing more than 90% of the business growing mid-single digits. Cash generation supports the story: $1.328 billion of Operating Cash Flow in the first half against $233 million of Capital Expenditure . Capital deployment has been aggressive, a $2.0 billion accelerated share repurchase inside the quarter, $2.25 billion of buybacks across the half, and $2.1 billion of debt retired. Gross debt still stood at $17.28 billion against $816 million of cash.

Pumps and platforms remain the swing Factor

The unresolved operational item is Alaris. BD continues to describe the infusion system's replacement and remediation as dependent on customer readiness, Supply continuity and engagement with the FDA, without committing to a US return-to-market date. Connected Care's mid-single-digit growth suggests recovery is under way, but the segment is not yet compounding at the rate a normalized pump Franchise would imply.

Elsewhere, the product cadence is steady rather than spectacular: the Elyra thulium fiber laser for kidney stone care launched in May 2026, and the CentroVena One insertion system won a Vizient Innovative Technology contract in June. These are share-gain products in adjacent hospital workflows, not new markets.

The case for a re-rating, and against one

The bull argument is arithmetic. BD trades on a forward price/earnings ratio of 12.57 with a 6.69% free cash flow yield and a 2.54% Dividend Yield . Medtronic, a larger and slower-growing peer, trades at 14.35 times forward earnings; Baxter, unprofitable on a trailing basis, at 12.44 times. A company generating high-single-digit free cash flow yields, shrinking its share count and no longer carrying a structurally slower research-tools business ought to close some of that gap.

The bear argument is equally arithmetic. Currency-neutral growth of 2.6% is not a growth rate that earns a premium multiple, and the strongest segment is the smallest driver of profit. BioPharma Systems is shrinking. China's volume-based procurement continues to compress prices, and BD's own guidance language flags US tariffs as an unquantified risk. Net debt of roughly $16.5 billion limits how much more the company can buy back before deleveraging takes priority.

Trailing multiples are unreliable here. The reported trailing P/E of 28.75 and EV/sales of 2.79 are calculated on twelve-month figures that still contain the divested businesses; on a continuing-operations run-rate closer to $19 billion, Enterprise value of $62.1 billion implies roughly 3.3 times sales. The consensus 12-month target across 14 analysts is $180.25, about 9% above the last close, a market pricing execution, not transformation.

What investors get on 6 August

The third-quarter release is the first clean read on whether the reset is translating into Margin expansion and whether management tightens or lifts the top of its EPS range. Beyond that, the fiscal fourth quarter and initial fiscal 2027 guidance in early November will show what a full year of standalone BD Economics looks like, and whether the answer to the question in this headline is growth, or simply a cheaper, tidier company.

Upcoming Catalysts

  • Fiscal Q3 2026 results, 8:00 a.m. ET. The second full post-separation quarter; watch organic growth by segment, adjusted margin, and any narrowing of the $12.52–$12.72 EPS range.
  • Fiscal Q4 and full-year fiscal 2026 results, expected early November 2026. First full-year standalone financials and initial fiscal 2027 guidance.
  • Alaris US return-to-market progress. BD has given no committed date; any FDA milestone would materially change the Connected Care growth outlook.
  • Further capital deployment. BD has already executed $2.25 billion of buybacks in the fiscal first half; the pace of remaining repurchases versus debt paydown is a live decision.

Principal Risks

  • Organic growth stall. Currency-neutral growth of 2.6% leaves little cushion; a soft quarter in Medical Essentials or a further BioPharma Systems decline would undercut the simplification thesis.
  • Alaris uncertainty. Replacement and remediation timing remains tied to FDA engagement, supply continuity and customer readiness, with no public target date.
  • Leverage. Gross debt of $17.28 billion against $816 million of cash constrains both buybacks and Acquisition capacity if cash conversion weakens.
  • China and tariffs. Volume-based procurement continues to pressure Chinese pricing, and BD's guidance explicitly treats US Tariff outcomes as unresolved.
  • Post-separation dis-synergies. Losing a high-margin diagnostics business has already pushed half-year adjusted EPS down 3.4%; stranded costs could persist longer than modeled.

Conclusion

The Waters combination closed; BD shareholders received about 0.135 Waters shares per BD share plus a 39.2% stake in the combined company, and BD banked a $4 billion cash distribution. Set against that: Currency-neutral growth of 2.6% leaves little cushion; a soft quarter in Medical Essentials or a further BioPharma Systems decline would undercut the simplification thesis. That tension shows up in the valuation: At $165.62, BDX trades on a 12.57 forward P/E with a 6.69% free cash flow yield, a discount to Medtronic that reflects slow organic growth and unresolved Alaris timing. The next real test: Fiscal Q3 2026 results, 8:00 a.m. ET. The second full post-separation quarter; watch organic growth by segment, adjusted margin, and any narrowing of the $12.52–$12.72 EPS range.

This article is for informational purposes only and does not constitute Investment advice or a recommendation to buy, sell, or hold any security. Share prices can rise or fall, and past performance does not guarantee future results. Investors should conduct independent research and consult a licensed financial adviser before making investment decisions.